Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 8/20 | 0.38 |
| ▸ | ALDH1A2 | O94788 | 7/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938576 | 0.77 | PIK3CD (1.00) | PIK3CDPIK3R1 | |
| SCHEMBL3620930 | 0.77 | PIK3CD (0.48) | PIK3CDSMN1; SMN2ALDH1A1ALDH1A3ALDH1A2 | |
| SCHEMBL17718372 | 0.75 | SMN1; SMN2 (0.47) | PIK3CDCYP1A2CYP2C9SMN1; SMN2NPSR1 | |
| SCHEMBL940736 | 0.74 | PIK3CD (0.56) | PIK3CDALDH1A1ALDH1A3ALDH1A2PIK3R1 | |
| SCHEMBL22854757 | 0.72 | PIK3CB (0.48) | PIK3CDCYP1A2CYP2C9SMN1; SMN2NPSR1 | |
| SCHEMBL22854483 | 0.72 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL22854703 | 0.71 | PIK3CG (0.55) | PIK3CDPIK3R1 | |
| SCHEMBL22854676 | 0.71 | PIK3CD (0.61) | PIK3CDPIK3R1 | |
| SCHEMBL17718365 | 0.70 | SMN1; SMN2 (0.47) | PIK3CDCYP1A2CYP2C9SMN1; SMN2NPSR1 | |
| SCHEMBL17718358 | 0.70 | PIK3CD (0.40) | PIK3CDCYP1A2CYP2C9SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| WO-2009064802-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ELI LILLY & CO. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | PIK3CD, PI4KB, PI4KA | PIK3CD 1/4885CYP1A2 3964/4885CYP2C9 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.